Alkermes Plc at JPMorgan Healthcare Conference Transcript
&-
Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42 Annual Healthcare Conference today with Alkermes. Richard Pops, the company CEO is going to give a presentation on the business and then we're going to go into Q&A after that.
If you have a question in the room, you can raise your hand, and we'll bring you a microphone or you can submit questions through the portal. But with that, let me that's over to Richard.
&
Great, thank you, Jess. I'm joined here with via Blair Jackson and Iain Brown as well. So good morning, everybody. So I've been looking forward to giving this presentation for a couple of years. This is a new company. Alkermes in 2024 is a profitable pure play company in the aspect of the biopharmaceutical industry that is taking on, I think, a renewed level of strategic importance in this neuroscience.
So we'll talk about that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |